Seminars in Nuclear Medicine
Volume 37, Issue 6 , Pages 440-450 , November 2007

3,4-Dihydroxy-6-[18F]-Fluoro-L-Phenylalanine Positron Emission Tomography in Patients With Central Motor Disorders and in Evaluation of Brain and Other Tumors

  • John P. Seibyl, MD
    • ,
  • Wei Chen, MD, PhD
    • ,
  • Daniel H.S. Silverman, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Daniel H.S. Silverman, MD, PhD, Ahmanson Biological Imaging Division, UCLA Medical Center, CHS AR-144, MC694215, Los Angeles, CA 90095-6942.

References 

  1. Garnett ES, Firnau G, Nahmias C, et al. Striatal dopamine metabolism in living monkeys examined by positron emission tomography. Brain Res. 1983;280:169–171
  2. Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature. 1983;305:137–138
  3. Herholz K, Heiss WD. Positron emission tomography in clinical neurology. Mol Imaging Biol. 2004;6:239–269
  4. Yahr MD. Early recognition of Parkinson’s disease. Hosp Pract (Off Ed). 1981;16:65–7277-80
  5. Fahn S. Description of Parkinson’s disease as a clinical syndrome. Ann N Y Acad Sci. 2003;991:1–14
  6. Fahn S. Controversies in the therapy of Parkinson’s disease. Adv Neurol. 1996;69:477–486
  7. Markham CH, Diamond SG. Long-term follow-up of early dopa treatment in Parkinson’s disease. Ann Neurol. 1986;19:365–372
  8. Wermuth L. Outpatient treatment of Parkinson’s disease. Eur Neurol. 1988;28:152–155
  9. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351:2498–2508
  10. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287:1653–1661
  11. Rakshi JS, Pavese N, Uema T, et al. A comparison of the progression of early Parkinson’s disease in patients started on ropinirole or L-dopa: An 18F-dopa PET study. J Neural Transm. 2002;109:1433–1443
  12. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003;54:93–101
  13. Swope DM. Rapid treatment of “wearing off” in Parkinson’s disease. Neurology. 2004;62(suppl 4):S27–S31
  14. Obeso JA, Rodriguez-Oroz M, Marin C, et al. The origin of motor fluctuations in Parkinson’s disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology. 2004;62(suppl 1):S17–S30
  15. Elm JJ, Goetz CG, Ravina B, et al. A responsive outcome for Parkinson’s disease neuroprotection futility studies. Ann Neurol. 2005;57:197–203
  16. Calne D, Schulzer M, Mak E, et al. Treatment for the progression of Parkinson’s disease. Lancet Neurol. 2005;4:206
  17. Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: Mysteries, myths, and misconceptions. JAMA. 2004;291:358–364
  18. Schapira AH. Disease modification in Parkinson’s disease. Lancet Neurol. 2004;3:362–368
  19. Lang AE, Obeso JA. Challenges in Parkinson’s disease: Restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol. 2004;3:309–316
  20. Koller WC, Cersosimo MG. Neuroprotection in Parkinson’s disease: An elusive goal. Curr Neurol Neurosci Rep. 2004;4:277–283
  21. Johnston TH, Brotchie JM. Drugs in development for Parkinson’s disease. Curr Opin Invest Drugs. 2004;5:720–726
  22. Drucker-Colin R, Verdugo-Diaz L. Cell transplantation for Parkinson’s disease: Present status. Cell Mol Neurobiol. 2004;24:301–316
  23. Dlamini Z, Mbita Z, Zungu M. Genealogy, expression, and molecular mechanisms in apoptosis. Pharmacol Ther. 2004;101:1–15
  24. Clarke CE. Neuroprotection and pharmacotherapy for motor symptoms in Parkinson’s disease. Lancet Neurol. 2004;3:466–474
  25. Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol. 1990;28:547–555
  26. Boja JW, Patel A, Carroll FI, et al. [125I]RTI-55: A potent ligand for dopamine transporters. Eur J Pharmacol. 1991;194:133–134
  27. Brooks DJ. Functional imaging in relation to parkinsonian syndromes. J Neurol Sci. 1993;115:1–17
  28. Brucke T, Kornhuber J, Angelberger P, et al. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT (Binding kinetics in the human brain). J Neural Transm Gen Sect. 1993;94:137–146
  29. Innis RB, Seibyl JP, Scanley BE, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA. 1993;90:11965–11969
  30. Mozley PD, Schneider JS, Acton PD, et al. Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson’s disease and in healthy volunteers. J Nucl Med. 2000;41:584–589
  31. Huang WS, Chiang YH, Lin JC, et al. Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson’s disease patients. J Nucl Med. 2003;44:999–1005
  32. Brooks DJ. Detection of preclinical Parkinson’s disease with PET. Geriatrics. 1991;46(suppl 1):25–30
  33. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56:33–39
  34. Quinn N. Parkinsonism—recognition and differential diagnosis. BMJ. 1995;310:447–452
  35. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson’s disease. Age Ageing. 1999;28:99–102
  36. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–184
  37. Rajput DR. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1993;56:938–939
  38. Seibyl J, Jennings D, Tabamo R, Marek K. The role of neuroimaging in the early diagnosis and evaluation of Parkinson’s disease. Minerva Med. 2005;96:353–364
  39. Varrone A, Marek KL, Jennings D, et al. [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson’s disease and multiple system atrophy. Mov Disord. 2001;16:1023–1032
  40. Kim YJ, Ichise M, Ballinger JR, et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord. 2002;17:303–312
  41. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol. 2005;62:378–382
  42. Au WL, Adams JR, Troiano AR, et al. Parkinson’s disease: in vivo assessment of disease progression using positron emission tomography. Brain Res Mol Brain Res. 2005;134:24–33
  43. Sossi V, de la Fuente-Fernandez R, Holden JE, et al. Changes of dopamine turnover in the progression of Parkinson’s disease as measured by positron emission tomography: Their relation to disease-compensatory mechanisms. J Cereb Blood Flow Metab. 2004;24:869–876
  44. Seibyl J, Jennings D, Tabamo R, et al. Neuroimaging trials of Parkinson’s disease progression. J Neurol. 2004;251(suppl 7):vII9–vII13
  45. Pirker W, Holler I, Gerschlager W, et al. Measuring the rate of progression of Parkinson’s disease over a 5-year period with beta-CIT SPECT. Mov Disord. 2003;18:1266–1272
  46. Schwarz J, Storch A, Koch W, et al. Loss of dopamine transporter binding in Parkinson’s disease follows a single exponential rather than linear decline. J Nucl Med. 2004;45:1694–1697
  47. de la Fuente-Fernandez R, Sossi V, Huang Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson’s disease: Implications for dyskinesias. Brain. 2004;127:2747–2754
  48. Snow B. Objective measures for the progression of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2003;74:287
  49. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord. 2003;18:1415–1423
  50. Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson’s disease: Design and methods of the CALM-PD Study. Clin Neuropharmacol. 2000;23:34–44
  51. Morrish PK. REAL and CALM: What have we learned?. Mov Disord. 2003;18:839–840
  52. Marek KL, Seibyl JP, Zoghbi SS, et al. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology. 1996;46:231–237
  53. Braak H, Del K, Tredici U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197–211
  54. Braak H, Rub U, Gai WP, et al. Tredici, Idiopathic Parkinson’s disease: Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. 2003;110:517–536
  55. Kim SE, Choi JY, Choe YS, et al. Serotonin transporters in the midbrain of Parkinson’s disease patients: a study with 123I-beta-CIT SPECT. J Nucl Med. 2003;44:870–876
  56. Murai T, Muller U, Werheid K, et al. In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2001;13:222–228
  57. Jemal A, Murray T, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2005;55:10–30
  58. In:  Kleihurs P,  Cavenee WK editor. Pathology and genetics of tumors of the nervous system (World Health Organization classification of tumors). Lyon, France: IARC Press; 2000;
  59. Posner JB. Neurologic complications of cancer. Philadelphia: E.A. Davis; 1995;
  60. Kleihues P, Cavenee WK. Pathology and Genetics of Tumors of the Nervous System. Lyon: IARC Press; 2000;
  61. Kleihues P, Ohgaki H. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64:479–489
  62. Levivier M, Becerra A, De Witte O, et al. Raidiation necrosis or recurrence. J Neurosurg. 1996;84:148–149
  63. Del Sole A, Falini A, Ravasi L, et al. Anatomical and biochemical investigation of primary brain tumours. Eur J Nucl Med. 2001;28:1851–1872
  64. Watling CJ, Lee DH, Macdonald DR, et al. Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol. 1994;12:1886–1889
  65. Ishiwata K, Kutota K, Murakami M, et al. Re-evaluation of amino acid PET studies: Can the protein synthesis rates in brain and tumor tissues be measured in vivo?. J Nucl Med. 1993;34:1936–1943
  66. Jager PL, Vaalburg W, Pruim J, et al. Radiolabeled amino acids: Basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432–445
  67. Herholz K, Holzer T, Bauer B, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50:1316–1322
  68. Laverman P, Boerman OC, Corstens FHM, et al. Fluorinated amino acids for tumour imaging with positron emission tomography. Eur J Nucl Med. 2002;29:681–690
  69. Weber WA, Wester HJ, Grosu AL, et al. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: Initial results of a comparative study. Eur J Nucl Med. 2000;27:542–549
  70. Becherer A, Karanikas G, Szabo M, et al. Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging. 2003;30:1561–1567
  71. Bethien-Baumann B, Bredow J, Burchert W, et al. 3-O-Methyl-6-[18F]fluoro-L-DOPA and its evaluation in brain tumour imaging. Eur J Nucl Med Mol Imaging. 2003;30:1004–1008
  72. Chen W, Silverman DHS, Delaloye S, et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006;47:904–911
  73. Jager PL, Vaalburg W, Prium J, et al. Radiolabeled amino acids: Basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432–445
  74. Isselbacher KJ. Sugar and amino acid transport by cells in culture: Differences between normal and malignant cells. N Engl J Med. 1972;286:929–933
  75. Busch H, Davis JR, Honig GR, et al. The uptakes of a variety of amino acids into nuclear proteins of tumors and other tissues. Cancer Res. 1959;19:1030–1039
  76. Miyagawa T, Oku T, Uehara H, et al. “Facilitated” amino acid transport is upregulated in brain tumors. J Cereb Blood Flow Metab. 1998;18:500–509
  77. Laverman P, Boerman OC, Corstens FHM, et al. Fluorinated amino acids for tumor imaging with positron emission tomography. Eur J Nucl Med. 2002;29:681–690
  78. Sasajima T, Miyagawa T, Oku T, et al. Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines. Eur J Nucl Med Mol Imaging. 2004;31:1244–1256
  79. Roelcke U, Radu EW, von Ammon K, et al. Alteration of blood-brain barrier in human brain tumors: Comparison of [18F]fluorodeoxyglucose, [11C]methionine and rubidium-82 using PET. J Neurol Sci. 1995;132:20–27
  80. Bergmann R, Pietzsch J, Fuechtner F, et al. 3-O-Methyl-6-18F-fluoro-L-Dopa, a new tumor imaging agent: Investigation of transport mechanism in vitro. J Nucl Med. 2004;45:2116–2122
  81. Hustinx R, Pourdehnad M, Kaschten B, et al. PET imaging for differentiating recurrent brain tumor from radiation necrosis. Radiol Clin North Am. 2005;43:35–47
  82. Giglio P, Gilbert HR. Cerebral radiation necrosis. Neurologist. 2003;9:180–188
  83. Langleben DD, Segall GM. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med. 2000;41:1861–1867
  84. Tsuyuguchi N, Sunada I, Iwai Y, et al. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: Is a differential diagnosis possible?. J neurosurg. 2003;98:1056–1064
  85. Spaeth N, Wyss MT, Weber B, et al. Uptake of 18F-fluorocholine, 18F-fluoroehtyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence. J Nucl Med. 2004;45:1931–1938
  86. De Witte O, Levivier M, Violon P, et al. Prognostic value of positron emission tomography with [18F]fluoro-2-D-glucose in the low-grade glioma. J Neurosurgy. 1996;39:470–477
  87. Ricci PE, Karis JP, Heiserman JE, et al. Differentiaing recurrent tumor from radiation necrosis: Time for re-evaluation of positron emission tomography ?. Am J Neuroradiol. 1998;19:407–413
  88. Heiss WD, Wienhard K, Wagner R, et al. F-Dopa as an amino acid tracer to detect brain tumors. J Nucl Med. 1996;37:1180–1182
  89. Koopmans KP, de Vries GE, Kema IP, et al. Staging of carcinoid tumors with 18F-DOPA PET: A prospective, diagnostic study. Lancet Oncol. 2006;7:728–734
  90. Montravers F, Grahek D, Kerrou K, et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?. J Nucl Med. 2006;47:1455–1462
  91. Kauhanen S, Seppanen M, Minn H, et al. Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients. J Clin Endocrinol Metab. 2007;92:1237–1244
  92. Ribeiro MJ, De Lonlay P, Delzescaux T, et al. Characterization of hyperinsulism in infancy assessed with PET and 18F-fluoro-L-DOPA. J Nucl Med. 2005;46:560–566
  93. Ambrosini V, Tomassetti P, Rubello D, et al. Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumors. Nucl Med Commun. 2007;28:473–477
  94. Hoegerle S, Ghanem N, Altehoefer C, et al. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging. 2003;30:689–694
  95. Hoegerle S, Altehoefer C, Ghanem N, et al. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001;28:64–71
  96. Hoegerle S, Nitzsche E, Altehoefer C, et al. Pheochromocytomas: detection with 18F DOPA whole body PET—initial results. Radiology. 2002;222:507–512

PII: S0001-2998(07)00088-8

doi: 10.1053/j.semnuclmed.2007.08.002

Seminars in Nuclear Medicine
Volume 37, Issue 6 , Pages 440-450 , November 2007

Article Tools

* Image Usage & Resolution